https://www.fool.com/earnings/call-transcripts/2020/10/28/pfizer-pfe-q3-2020-earnings-call-transcript/

Operator

Your next question comes from Tim Anderson from Wolfe Research.

Tim Anderson -- Wolfe Research -- Analyst

Thank you. I have a non-COVID question which is following the initial news where you said you spin out Upjohn, you described the company is likely to pay less of its free cash back to shareholders in the form of dividends and buybacks. And I'm wondering if that's still the current view, especially if you can achieve the revenue growth targets, you've given of at least 6% over the next several years. And that question ties into another question on M&A.

What's the upper limit on the size of the deals you might be considering, should we assume these will likely be sub-$10 billion transactions, or are larger deals also potentially on the table?

Albert Bourla -- Chairman and Chief Executive Officer

Thank you, Tim, for asking a non-COVID question. Appreciate it, really. And also, it came at the time that I thought Frank will not have a chance to speak, but now, we are giving him the exact right forum. So, Frank, take it from here.

Frank D'Amelio -- Chief Financial Officer

Thank you, Albert, and Tim, thanks for the question. So on M&A, we always say we never say never because one of the nice things about being part of Pfizer is we have the firepower to pretty much do any kind of a deal we want. And I think we've been able to demonstrate that in the past. So I wouldn't limit us or cap us on some specific dollar amount given the firepower that we have.

Albert mentioned earlier, our focus has been mid Phase, Phase 2, Phase 3, kind of things that would impact our revenue base, '24, '25, '26. But in terms of capacity, quite frankly, we're very much unlimited. Strong balance sheet, strong capital structure, strong investment grade, we generate lots of operating cash flow. So you know, we are in a very good position quite frankly to be very proactive as we need to be on M&A.

And then in terms of your Upjohn question, from my perspective we get the Upjohn deal done, we formed Viatris, we're going to get $12 billion in cash, our intent with that $12 billion in cash is to pay down debt given we're transferring, give or take, about $4 billion of EBITDA to Upjohn, but our capital deployment priorities don't change as a result of that transaction. We'll still return capital to our shareholders as we have been doing. We'll continue to invest in the business, in our pipeline obviously and capital. And then we'll continue to invest in M&A.

So from my perspective capital priorities don't change and in terms of M&A capacity we're fortunate enough where we really have lots of capacity, lots of firepower.

Chuck Triano -- Senior Vice President of Investor Relations

Thank you, Frank. Thanks, Tim. And we move to our next question, please.